Last reviewed · How we verify
Glimepiride or gliclazide
Glimepiride and gliclazide stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Glimepiride and gliclazide stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Glimepiride or gliclazide |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Sulfonylurea |
| Target | ATP-sensitive potassium channel (KATP channel) / Sulfonylurea receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Both drugs are second-generation sulfonylureas that bind to sulfonylurea receptors on the ATP-sensitive potassium channels in pancreatic beta cells. This binding closes the channels, depolarizes the cell membrane, and triggers calcium influx, which stimulates the release of stored insulin. This mechanism lowers blood glucose in patients with type 2 diabetes by increasing endogenous insulin secretion.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Dizziness
- Headache
- Gastrointestinal disturbances
Key clinical trials
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin (PHASE3)
- Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263) (PHASE4)
- Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan (PHASE4)
- Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (PHASE3)
- A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313) (PHASE4)
- A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253) (PHASE3)
- Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glimepiride or gliclazide CI brief — competitive landscape report
- Glimepiride or gliclazide updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI